Paper34936729
Integrated multi-omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer.
Meng J and 9 others. Clin Transl Med, 2021. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Integrated multi-omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer. Papers, record 34936729. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34936729
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Integrated multi-omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Androgen Receptor Antagonists | Major topic |
| Prostatic Neoplasms | Major topic |
| Humans | |
| Male | |
| Molecular Typing | |
| Signal Transduction |
Source PubMed
Grants11
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 81630019 | National Natural Science Foundation of China | PubMed | ||
| 81870519 | National Natural Science Foundation of China | PubMed | ||
| 81802827 | National Natural Science Foundation of China | PubMed | ||
| 81973145 | National Natural Science Foundation of China | PubMed | ||
| gxyqZD2019018 | Distinguished Young Scholar of Anhui Colleges | PubMed | ||
| 2019YFC1711000 | National Key R&D Program of China | PubMed | ||
| BE2020694 | Key R&D Program of Jiangsu Province | PubMed | ||
| 2017ZHYX02 | Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province | PubMed | ||
| 2017A030313800 | Natural Science Foundation of Guangdong Province | PubMed | ||
| KJ2019A0278 | Key project of provincial natural science research project of Anhui Colleges | PubMed | ||
| 2017070802D148 | Anhui Province special program for guiding local science and technology development | PubMed |
Source PubMed
References10
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32820797 | Aldosterone, Inflammation, Immune System, and Hypertension. | Am J Hypertens | 2021 | https://conductscience.org/library/papers/32820797 | PubMed |
| 2 | 33315104 | MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. | Bioinformatics | 2021 | https://conductscience.org/library/papers/33315104 | PubMed |
| 3 | 29318445 | Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. | Cancer Metastasis Rev | 2018 | https://conductscience.org/library/papers/29318445 | PubMed |
| 4 | 31061129 | Genomic correlates of clinical outcome in advanced prostate cancer. | Proc Natl Acad Sci U S A | 2019 | https://conductscience.org/library/papers/31061129 | PubMed |
| 5 | 25043044 | PVT1 dependence in cancer with MYC copy-number increase. | Nature | 2014 | https://conductscience.org/library/papers/25043044 | PubMed |
| 6 | 28988769 | Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. | Cell | 2017 | https://conductscience.org/library/papers/28988769 | PubMed |
| 7 | 28494073 | Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. | JAMA Oncol | 2017 | https://conductscience.org/library/papers/28494073 | PubMed |
| 8 | 26544944 | The Molecular Taxonomy of Primary Prostate Cancer. | Cell | 2015 | https://conductscience.org/library/papers/26544944 | PubMed |
| 9 | 30207593 | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2018 | https://conductscience.org/library/papers/30207593 | PubMed |
| 10 | 33338321 | Immune response drives outcomes in prostate cancer: implications for immunotherapy. | Mol Oncol | 2021 | https://conductscience.org/library/papers/33338321 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42939971 | A Prognostic Model for Prostate Cancer Screened from Stress Granule-Related Genes: An Integrated Bioinformatic Analysis and Experimental Verification of SPAG5 Function. | Biomedicines | 2026 | https://conductscience.org/library/papers/42939971 | PubMed |
| 42536695 | Concordant RNA-protein evidence and human tissue metabolomics prioritize UPP1-associated nucleotide remodeling in prostate cancer. | PLoS One | 2026 | https://conductscience.org/library/papers/42536695 | PubMed |
| 41609946 | Unraveling heterogeneity in LUAD via multi-omics integration: molecular classification and therapeutic implications. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41609946 | PubMed |
| 40038532 | Multi-omics clustering analysis carries out the molecular-specific subtypes of thyroid carcinoma: implicating for the precise treatment strategies. | Genes Immun | 2025 | https://conductscience.org/library/papers/40038532 | PubMed |
| 39406474 | Prognosis-oriented molecular subtypes of retroperitoneal liposarcoma. | Clin Transl Med | 2024 | https://conductscience.org/library/papers/39406474 | PubMed |
| 39168102 | Proteomic landscape profiling of primary prostate cancer reveals a 16-protein panel for prognosis prediction. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/39168102 | PubMed |
| 39154013 | Telomerase related molecular subtype and risk model reveal immune activity and evaluate prognosis and immunotherapy response in prostate cancer. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/39154013 | PubMed |
| 38868222 | Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy. | Imeta | 2023 | https://conductscience.org/library/papers/38868222 | PubMed |
| 38833013 | Deciphering the role of zinc homeostasis in the tumor microenvironment and prognosis of prostate cancer. | Discov Oncol | 2024 | https://conductscience.org/library/papers/38833013 | PubMed |
| 38721587 | Integrated immunogenomic analysis of single-cell and bulk profiling reveals novel tumor antigens and subtype-specific therapeutic agents in lung adenocarcinoma. | Comput Struct Biotechnol J | 2024 | https://conductscience.org/library/papers/38721587 | PubMed |
| 38549156 | Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment. | Eur J Med Res | 2024 | https://conductscience.org/library/papers/38549156 | PubMed |
| 38125666 | From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine. | Health Inf Sci Syst | 2024 | https://conductscience.org/library/papers/38125666 | PubMed |
| 37950160 | A pathway activity-based proteomic classifier stratifies prostate tumors into two subtypes. | Clin Proteomics | 2023 | https://conductscience.org/library/papers/37950160 | PubMed |
| 37939258 | Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy. | Ann Med | 2023 | https://conductscience.org/library/papers/37939258 | PubMed |
| 37568655 | Advancements in MRI-Based Radiomics and Artificial Intelligence for Prostate Cancer: A Comprehensive Review and Future Prospects. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37568655 | PubMed |
| 36275733 | The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies. | Front Immunol | 2022 | https://conductscience.org/library/papers/36275733 | PubMed |
| 35741849 | Characterization of Immune-Based Molecular Subtypes and Prognostic Model in Prostate Adenocarcinoma. | Genes (Basel) | 2022 | https://conductscience.org/library/papers/35741849 | PubMed |
| 35682963 | From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35682963 | PubMed |
Genes28
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34936729
GET https://conductscience.org/api/papers/v1/34936729/genes?page=2